PHKG2
MOLECULAR TARGETphosphorylase kinase catalytic subunit gamma 2
PHKG2 (phosphorylase kinase catalytic subunit gamma 2) is targeted by 33 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting PHKG2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | gefitinib | 5.67 | 290 |
| 2 | alvocidib | 4.52 | 91 |
| 3 | tozasertib | 4.33 | 75 |
| 4 | vandetanib | 4.30 | 73 |
| 5 | ruxolitinib | 4.23 | 68 |
| 6 | nilotinib | 4.17 | 64 |
| 7 | bosutinib | 4.08 | 58 |
| 8 | bi 2536 | 4.01 | 54 |
| 9 | midostaurin | 3.85 | 46 |
| 10 | brigatinib | 3.81 | 44 |
| 11 | silmitasertib | 3.78 | 43 |
| 12 | nintedanib | 3.61 | 36 |
| 13 | pelitinib | 3.50 | 32 |
| 14 | bms 387032 | 3.47 | 31 |
| 15 | tae 684 | 3.43 | 30 |
| 16 | fedratinib | 3.40 | 29 |
| 17 | gilteritinib | 3.40 | 29 |
| 18 | sp 600125 | 3.22 | 24 |
| 19 | alectinib | 3.18 | 23 |
| 20 | dovitinib | 3.09 | 21 |
| 21 | lestaurtinib | 3.04 | 20 |
| 22 | pf 03758309 | 3.00 | 19 |
| 23 | danusertib | 2.94 | 18 |
| 24 | r 406 | 2.83 | 16 |
| 25 | k 252a | 2.83 | 16 |
| 26 | milciclib | 2.77 | 15 |
| 27 | pha 665752 | 2.71 | 14 |
| 28 | crenolanib | 2.71 | 14 |
| 29 | kw 2449 | 2.64 | 13 |
| 30 | su 014813 | 2.20 | 8 |
| 31 | Afatinib | 1.10 | 2 |
| 32 | sp600125 | 1.10 | 2 |
| 33 | alsterpaullone | 0.69 | 1 |
About PHKG2 as a Drug Target
PHKG2 (phosphorylase kinase catalytic subunit gamma 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 33 compounds with documented PHKG2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
PHKG2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.